Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1320)	7/10/2000 1:42:39 AM
From: dalroi	Read Replies (1) \| Respond to of 52153

Concerning IGEN i looked yesterday at the options :-) perhaps its beter to buy half position @ 18 sell 1 call 20 and 1 put 17.5 for evry 100 shares (august serie) yields +- 4$ if called you sell with 6$ gain ie 18 -4 = 16 gain is 4+2$ or 6/16 or +- 40ù if put you buy additional stock at +- 14$ if between you get 4$ for waiting or +- 20% not bad for 6w time. you could however miss the jump but so what then 40% in 6w cheers Stefaan

To: Biomaven who wrote (1320)	7/10/2000 1:18:24 PM
From: Biomaven	Respond to of 52153

Just a follow-up to my IGEN post. A 13G filed today confirms that Soros now appears to be out. It's hard to figure out the exact details, though. This Statement relates to Shares that were acquired by White Rock Management on behalf of certain institutional clients (the "White Rock Clients"), including, but not limited to, Quantum Partners LDC, a Cayman Islands exempted limited duration company ("Quantum Partners"). Effective July 7, 2000, no Shares are held for the account of Quantum Partners. Accordingly, each of SFM LLC, Mr. Soros and Mr. Druckenmiller shall no longer be considered a Reporting Person in connection with this Statement. In terms of total holdings, White Rock now reports a beneficial interest of around 1 million shares, against the 2.34 million from the last (including Soros) report. So there certainly has been significant selling, which goes a long way towards explaining the stock price. Of course from a valuation perspective, insistent selling (or for that matter, buying) largely unrelated to the company fundamentals is most likely to produce a "mispriced" stock. Of course we don't know for sure whether the Soros selling was related only to his change in strategy, or whether it also related to his view of the company. Interestingly, a filing today showed essentially no change in the Soros (via Perseus) holdings of VPHM preferred. Of course there might have been some shorting of the common by Soros that wouldn't be reflected in that filing. Peter

To: Biomaven who wrote (1320)	7/10/2000 6:13:43 PM
From: N/E PATSFAN	Respond to of 52153

[IGEN] Thanks for the info Peter. This bio looks undervalued to me if they potentially have tech to hone in on an individual's specific gene for therapy and they can resolve the litigation. I'll wait for a pullback or positive news before entering but this may go to 28 before a pullback. The white candle today may be predicting impending news ... any technicians out there who can read the candles?? Thanks, NEPF

To: Biomaven who wrote (1320)	7/11/2000 11:11:02 AM
From: RWReeves	Read Replies (1) \| Respond to of 52153

Don't feel too lonely in IGEN- Although I don't post a lot on diagnostics, I follow them and buy when they are silly cheap. I also have some IGEN, second time in it, previously quite a while ago. Pretty much concur- this is a situation validated by Roche and like their technology. Currently have also BLUD, ABAX, sold STAT recently. RWR